ERBB3 Antibody (ARP30252_P050)
- Known as:
- ERBB3 Antibody (ARP30252_P050)
- Catalog number:
- arp30252_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- ERBB3 Antibody (ARP30252_P050)
Related genes to: ERBB3 Antibody (ARP30252_P050)
- Gene:
- ERBB3 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 3
- Previous symbol:
- LCCS2
- Synonyms:
- HER3
- Chromosome:
- 12q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-15
- Date modifiied:
- 2019-04-23
Related products to: ERBB3 Antibody (ARP30252_P050)
Related articles to: ERBB3 Antibody (ARP30252_P050)
- Human epidermal growth factor receptor (HER) 3, encoded by the gene, transduces signals most effectively when dimerized with HER2. Although HER3 protein expression has been considered a poor prognostic factor in ovarian cancer, limited data exist on changes in HER3 protein expression and messenger RNA (mRNA) expression during recurrence. This study evaluated HER3/ERBB3 expression before and after recurrence and its association with prognosis using paired samples. We also evaluated HER2/ERBB2 expression. - Source: PubMed
Publication date: 2026/09/11
Yokosu KotaYamashita RiuFujii SatoshiTanabe HiroshiMukohara ToruSato SaoriKobayashi MakiOshima KeikoKimura HirokoTakahashi HiroyukiSaito MotoakiYamada KyosukeTakano HirokuniOkamoto AikouHarano Kenichi - Immune checkpoint inhibitors (ICIs), including anti-programmed cell death protein 1 (anti-PD-1) antibodies, have significantly improved outcomes in patients with metastatic non-small cell lung cancer (mNSCLC). However, substantial heterogeneity exists in clinical benefit, with some patients exhibiting early progression (EP) and others late progression (LP). To date, no biomarkers of EP versus LP disease have been implemented in clinical practice. Circulating tumor DNA (ctDNA) analysis represents a minimally invasive strategy for identifying such biomarkers. In this proof-of-concept study, we evaluated the performance of the TruSight Oncology 500 ctDNA (TSO500 ctDNA) panel and explored its feasibility to identify candidate variants associated with early and late disease progression under anti-PD-1 therapy. - Source: PubMed
Publication date: 2026/08/27
Rodriguez-Casanova AitorMondelo-Macía PatriciaLeon-Mateos LuisGarcía-González JorgeCosta-Fraga NicolásDubbelman JaimeGómez-García María ÁngelesLorenzo-Gómez IreneAbalo AliciaMuinelo-Romay LauraLópez-López RafaelDíaz-Lagares Angel - - Source: PubMed
Publication date: 2026/09/10
De Bacco FrancescaOrzan FrancescaErriquez JessicaCasanova ElenaBarault LudovicAlbano RaffaellaD'Ambrosio AntonioBigatto ViolaReato GigliolaPatanè MonicaPollo BiancaKuesters GeoffreyDell'Aglio CarmineCasorzo LauraPellegatta SerenaFinocchiaro GaetanoComoglio Paolo MBoccaccio Carla - Autologous CAR-T therapy has achieved notable success in B-cell malignancies, yet its broader application is constrained by high costs, protracted manufacturing timelines, and severe toxicities, including cytokine release syndrome (CRS) and graft-versus-host disease (GVHD). Natural killer (NK) cells offer a compelling off-the-shelf alternative, owing to their major histocompatibility complex-independent cytotoxicity and negligible GVHD risk. Among allogeneic NK sources, umbilical cord blood (UCB)-derived CAR-NK cells are distinguished by a CD56brightCD16-/dim phenotype, extended telomeres, and a transcriptional profile that facilitates >1,000-fold ex vivo expansion. These properties have supported extensive preclinical evaluation and early clinical translation. Preclinical studies have documented antitumor activity against CD19, CD123, PD-L1, ErbB3, and mesothelin, without evidence of CRS. In a landmark phase I/II trial (NCT03056339), 7 of 11 patients (64%) with relapsed or refractory CD19+ B-cell malignancies achieved complete remission, with no observed GVHD or neurotoxicity. However, relapses occurring within 2 to 3 months correlated with loss of detectable CAR-NK cells, highlighting limited in vivo persistence as a principal barrier to durable response. - Source: PubMed
Publication date: 2026/09/03
Lu KunCai Mei-LianLi JingLi Tao - Gastric cancer is a major global health issue, especially in advanced stages with metastasis. However, anti-angiogenic treatments such as ramucirumab target vascular endothelial growth factor, yet the exact mechanisms behind hematogenous metastasis remain unclear. This study analyzed RNA sequencing data from TCGA to identify angiogenesis-related genes in metastatic gastric cancer. - Source: PubMed
Publication date: 2026/08/31
Yoo JaeunKim Hyun MyongJeong KyoungyunYoo Yie-RiShin Ji-YeonLee SeunghoLee SeungbokLee Hye SeungPark Kyoung UnKong Seong-HoPark Do JoongLee Hyuk-JoonYang Han-Kwang